Long-Acting Amylin Analog Research Compound

Cagrilintide (5mg) will be supplied in Australia by Daza Enhanced with fast domestic shipping to all states and territories.

Cagrilintide is a long-acting analog of amylin — a pancreatic hormone co-secreted with insulin that contributes to satiety, gastric emptying, and post-meal glucose control. Unlike native amylin, which is short-acting and rapidly cleared, Cagrilintide is engineered for once-weekly research dosing and is one of the most-studied amylin-class compounds in current metabolic research.

Cagrilintide’s primary research interest is its complementary mechanism to GLP-1 agonists. While GLP-1 compounds like Semaglutide and Tirzepatide reduce appetite through incretin pathways, Cagrilintide acts via the amylin pathway — a separate, additive signal. The combination of Cagrilintide + Semaglutide (CagriSema) is the most-watched dual-mechanism compound in current Phase 3 weight management research, with trial data suggesting outcomes that rival the highest-performing tri-agonist compounds.

Key Research Areas

• Appetite & Satiety — Amylin pathway signalling for reduced food intake
• Body Weight Reduction — Studied as monotherapy and in combination with GLP-1 agonists
• CagriSema Research — Cagrilintide + Semaglutide is one of the most-watched compound combinations in Phase 3 weight-management trials
• Glycaemic Control — Studied for post-meal glucose modulation via slowed gastric emptying
• Comparative Research — Studied alongside Semaglutide, Tirzepatide, and Retatrutide as a complementary-mechanism compound

Supplied as lyophilized powder, verified by HPLC and mass spectrometry. 5mg per vial. Fast domestic shipping across Australia, with batch-specific CoA information available in our CoA Library.

⚠ For in-vitro research and laboratory use only. Not for human consumption.